Dr. Bonafide’s research focus is on developing, evaluating, and implementing interventions at the intersection of patient safety and technological innovation, and measuring the impacts of these interventions on children and families. His research includes methods drawn from clinical epidemiology, biostatistics, clinical informatics, systems engineering, and implementation science.
Dr. Maris investigates the molecular and genetic mechanisms contributing to the development and progression of neuroblastoma, a common childhood cancer. He also aims to develop new molecular diagnostic tests and less toxic, targeted therapies to treat relapsed or refractory neuroblastoma, including a major effort in immunotherapy discovery and development.
Dr. Zorc's work focuses on the intersection of interventional clinical research, quality improvement (QI), and clinical informatics. He has formal certification in epidemiology, QI methodology, and clinical informatics, and has participated in multi-center research networks, guideline and improvement collaboratives, and electronic health record development locally and nationally.
Dr. Mautone's research focuses on assessment and treatment of attention-deficit/hyperactivity disorder. She has expertise in family-school-health system collaboration, classroom consultation, and integrated behavioral health in primary care settings. She has a special interest in increasing access to high-quality, culturally competent care for underserved children and families.
Dr. Moorthy’s research focuses on liquid chromatography-tandem mass spectrometry assays for translational research. He is an expert in developing and validating analytical methods and their implementation for pediatric and adult clinical sample analysis.
Dr. Power's research focuses on the implementation of evidence-based interventions for children with attention-deficit/hyperactivity disorder (ADHD) in community settings, including schools and primary care practices. The emphasis of his work is on developing the capacity of professionals in the community to provide evidence-based care for children and adolescents with attention, behavior, and emotional difficulties.
Dr. Balis's research focuses on the clinical pharmacology of anticancer drugs, new drug development, and clinical trial design and endpoints. He studies the pharmacokinetics and pharmacodynamics of anticancer drugs and has applied pharmacological principles to clinical trial design and clinical drug development. He is developing new biomarkers to serve as surrogate endpoints of drug toxicity or efficacy in clinical trials.